Cartesian Therapeutics (RNAC) Total Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Total Liabilities data on file, last reported at $436.5 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 1.3% year-over-year to $436.5 million in Q1 2026; TTM through Mar 2026 was $436.5 million, a 1.3% increase from a year earlier, with the FY2025 full-year figure at $422.7 million, down 4.34% from the prior year.
• Total Liabilities for Q1 2026 stood at $436.5 million, up from $422.7 million in the prior quarter.
• Over the last five years, Total Liabilities for RNAC reached as high as $454.6 million in Q3 2024 and fell as low as $45.7 million in Q3 2023.
• Historically, Total Liabilities has averaged $286.9 million across 5 years, with a median of $408.5 million in 2025.
• Across the five-year window, Total Liabilities plunged 54.19% in 2022 and soared 894.56% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $72.1 million in 2022, then soared by 517.11% to $444.7 million in 2023, then dropped by 0.64% to $441.8 million in 2024, then slipped by 4.34% to $422.7 million in 2025, then climbed by 3.28% to $436.5 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $436.5 million in Q1 2026, $422.7 million in Q4 2025, and $408.5 million in Q3 2025.